DE60118186D1 - Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem) - Google Patents

Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem)

Info

Publication number
DE60118186D1
DE60118186D1 DE60118186T DE60118186T DE60118186D1 DE 60118186 D1 DE60118186 D1 DE 60118186D1 DE 60118186 T DE60118186 T DE 60118186T DE 60118186 T DE60118186 T DE 60118186T DE 60118186 D1 DE60118186 D1 DE 60118186D1
Authority
DE
Germany
Prior art keywords
pathological
growth factor
arteriogenesis
pigf
angiogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60118186T
Other languages
English (en)
Other versions
DE60118186T2 (de
Inventor
Peter Carmeliet
Desire Collen
Falco Sandro De
Ruvo Menotti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vlaams Instituut voor Biotechnologie VIB
Desire Collen Research Foundation vzw
Original Assignee
Vlaams Instituut voor Biotechnologie VIB
Desire Collen Research Foundation vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8171493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60118186(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vlaams Instituut voor Biotechnologie VIB, Desire Collen Research Foundation vzw filed Critical Vlaams Instituut voor Biotechnologie VIB
Application granted granted Critical
Publication of DE60118186D1 publication Critical patent/DE60118186D1/de
Publication of DE60118186T2 publication Critical patent/DE60118186T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
DE60118186T 2000-05-12 2001-05-10 Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem) Expired - Lifetime DE60118186T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00201714 2000-05-12
EP00201714 2000-05-12
PCT/EP2001/005478 WO2001085796A2 (en) 2000-05-12 2001-05-10 Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage

Publications (2)

Publication Number Publication Date
DE60118186D1 true DE60118186D1 (de) 2006-05-11
DE60118186T2 DE60118186T2 (de) 2006-12-28

Family

ID=8171493

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60118186T Expired - Lifetime DE60118186T2 (de) 2000-05-12 2001-05-10 Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem)

Country Status (10)

Country Link
US (8) US7482004B2 (de)
EP (1) EP1297016B1 (de)
AT (1) ATE321069T1 (de)
AU (2) AU6595301A (de)
CA (1) CA2407858C (de)
DE (1) DE60118186T2 (de)
DK (1) DK1297016T3 (de)
ES (1) ES2260234T3 (de)
PT (1) PT1297016E (de)
WO (1) WO2001085796A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1297016B1 (de) * 2000-05-12 2006-03-22 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem)
AU8473401A (en) * 2000-08-04 2002-02-18 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
GB2374870A (en) * 2001-01-26 2002-10-30 Thromb X Nv Use of genetically modified multicellular animals in the identification of drug target proteins
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
CA2444632A1 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
CA2444624A1 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
GB2384706A (en) * 2002-02-04 2003-08-06 Thromb X Nv Agent for the prevention or minimisation of post-operative adhesion formation and/or cell implantation
ITRM20020277A1 (it) * 2002-05-17 2003-11-17 Geymonat Spa Muteine del fattore di crescita placentare tipo 1, metodo di preparazione e loro applicazioni.
EP1517703B1 (de) * 2002-06-28 2007-03-21 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Plazenta-wachstumsfaktor als target für die behandlung von osteoporose
ATE394679T1 (de) 2002-11-16 2008-05-15 Dade Behring Marburg Gmbh Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen
GB0228409D0 (en) * 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
JP2007528355A (ja) * 2003-03-07 2007-10-11 アンジェスＭｇ株式会社 血管壁の炎症および新生内膜過形成を阻害する組成物および方法
BRPI0413876A (pt) 2003-08-29 2006-10-24 Pfizer tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos
BRPI0418102A (pt) 2003-12-23 2007-04-27 Pfizer derivados de quinolina
WO2005087812A1 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
EP1812064A4 (de) * 2004-11-19 2009-07-08 Cornell Res Foundation Inc Verwendung vaskulärer endothelwachstumsfaktor-rezeptor-1+-zellen bei der behandlung und überwachung von krebs und beim screening bei chemotherapie
MX2007011735A (es) 2005-03-24 2008-03-14 Thrombogenics Nv Anticuerpo anti-plgf novedoso.
DE102005022047A1 (de) * 2005-05-09 2006-11-30 Dade Behring Marburg Gmbh Bindungspartner des Plazentalen Wachstumsfaktors insbesondere gegen den Plazentalen Wachstumsfaktor gerichtete Antikörper, ihre Herstellung und Verwendung
WO2007003609A1 (en) * 2005-06-30 2007-01-11 Vib Vzw Treatment of liver cirrhosis and its complications
CN101534865A (zh) * 2005-10-19 2009-09-16 Ibc药品公司 生物活性装配体的制备方法及其用途
CN100355882C (zh) * 2005-12-05 2007-12-19 中国人民解放军军事医学科学院放射与辐射医学研究所 杂交瘤细胞株及其产生的抗人vegfr－3的单克隆抗体
AU2014200453B2 (en) * 2006-11-09 2015-06-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Differential gene expression in physiological and pathological angiogenesis
CA3025354A1 (en) * 2006-11-09 2008-05-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Differential gene expression in physiological and pathological angiogenesis
EP2185718B1 (de) 2007-08-03 2017-10-04 MUSC Foundation For Research Development Menschliche monoklonale antikörper und verfahren zu ihrer herstellung
RU2010133157A (ru) 2008-01-07 2012-02-20 Орто-Клиникал Дайэгностикс, Инк. (Us) Определение комплекса sflt-1:ангиогенный фактор
US20110059445A1 (en) 2008-03-28 2011-03-10 Paul Rutgeerts Mucosal gene signatures
ES2592902T3 (es) 2008-10-02 2016-12-02 Vib Vzw Inhibición del PlGF para el tratamiento de la leucemia positiva para el cromosoma Filadelfia
GB0914318D0 (en) 2009-08-14 2009-09-30 Medical Res Council Method
DE102010013555A1 (de) 2010-03-31 2011-10-06 Christian Hamm Verwendung der Biomarker sFlt und PIGF in der Diagnose und Therapie der pulmonalen Hypertonie
EP2704745B1 (de) 2011-05-05 2016-12-14 Duke University Verfahren zur entwicklung einer prognose für bauchspeicheldrüsenkrebs und zur vorhersage des ansprechens auf krebstherapeutika
EP2785739B1 (de) 2011-12-01 2017-03-15 ThromboGenics N.V. Verbesserung eines augendrucksenkungsergebnisses
NZ630551A (en) 2012-04-20 2017-11-24 Merus Nv Methods and means for the production of ig-like molecules
EP3426685A1 (de) 2016-03-10 2019-01-16 Oxurion NV Hintere okularfibrosehemmung durch antagonisierung des plazentalen wachstumsfaktors
WO2017201166A1 (en) * 2016-05-17 2017-11-23 Duke University Methods of predicting responsiveness of a cancer to a vegf targeting agent and methods of prognosing and treating cancer
AU2019337806A1 (en) * 2018-09-11 2021-05-13 Anbition S.R.L. Peptides and medical uses thereof
JP2022500463A (ja) * 2018-09-11 2022-01-04 アンビション ソチエタ レスポンサビリタ リミタータ ペプチドおよびその医学的使用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
IT1242149B (it) * 1990-09-27 1994-02-16 Consiglio Nazionale Ricerche Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi
US20010021382A1 (en) * 1991-03-29 2001-09-13 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1993020229A1 (en) * 1992-04-03 1993-10-14 Genentech, Inc. ANTIBODIES TO ALPHAvBETA3 INTEGRIN
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US6846839B1 (en) * 1995-06-07 2005-01-25 Sugen, Inc. Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
US6986890B1 (en) * 1996-11-21 2006-01-17 Kyowa Hakko Kogyo Co., Ltd. Anti-human VEGF receptor Flt-1 monoclonal antibody
GB9723780D0 (en) * 1997-11-12 1998-01-07 Univ Manchester Regulation of ocular angiogenesis
ES2389387T3 (es) * 1998-03-17 2012-10-25 Genentech, Inc. Polipéptidos homólogos de VEGF y de BMP1
EP1079688A1 (de) 1998-05-26 2001-03-07 Innogenetics N.V. Verfahren zur expansion von primat b-zellen selektiv in immunitätsbeeinsträchtigten mäuse und produktion von hoher anzahl an antigenspezifische b-lymphozyten für die produktion von primat monoklonale antikörper
WO2001057067A1 (en) * 2000-02-04 2001-08-09 Supratek Pharma Inc. Ligand for vascular endothelial growth factor receptor
EP1297016B1 (de) * 2000-05-12 2006-03-22 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem)
EP1517703B1 (de) * 2002-06-28 2007-03-21 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Plazenta-wachstumsfaktor als target für die behandlung von osteoporose
MX2007011735A (es) * 2005-03-24 2008-03-14 Thrombogenics Nv Anticuerpo anti-plgf novedoso.
WO2007003609A1 (en) * 2005-06-30 2007-01-11 Vib Vzw Treatment of liver cirrhosis and its complications

Also Published As

Publication number Publication date
US20090162354A1 (en) 2009-06-25
CA2407858A1 (en) 2001-11-15
US20120263710A1 (en) 2012-10-18
ATE321069T1 (de) 2006-04-15
ES2260234T3 (es) 2006-11-01
WO2001085796A3 (en) 2002-04-04
DE60118186T2 (de) 2006-12-28
DK1297016T3 (da) 2006-07-10
AU6595301A (en) 2001-11-20
US20030180286A1 (en) 2003-09-25
EP1297016A2 (de) 2003-04-02
CA2407858C (en) 2015-10-27
AU2001265953B2 (en) 2005-09-29
US7482004B2 (en) 2009-01-27
PT1297016E (pt) 2006-07-31
US20130177565A1 (en) 2013-07-11
US20130183310A1 (en) 2013-07-18
US20130177564A1 (en) 2013-07-11
US20090074765A1 (en) 2009-03-19
US20090238826A1 (en) 2009-09-24
WO2001085796A2 (en) 2001-11-15
EP1297016B1 (de) 2006-03-22

Similar Documents

Publication Publication Date Title
DE60118186D1 (de) Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem)
DE60231804D1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
ATE328612T1 (de) Therapeutische zusammensetzungen zur behandlung von schleimhypersekretion
IS2782B (is) Lyfja- og snyrtivörusamsetningar sem ná yfir þorskserínprótínasa og lyfja- og snyrtivörunotkun þeirra
DE10346913A1 (de) Acylhydrazonderivate
ATE451930T1 (de) Verwendung von il-18-hemmern zur behandlung oder prävention von sepsis
TW200621748A (en) Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines
ATE319465T1 (de) Therapeutische verwendung von extrakten aus sophora flavescens oder sophora subprostrata
ATE421877T1 (de) Verwendung von totarol zur behandlung von pruritus
DE60141636D1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
ATE446514T1 (de) VERWENDUNG VON ßHYPOXIA INDUCIBLE FACTOR 2ALPHAß ZUR BEHANDLUNG VON ßNEONATAL RESPIRATORY DISTRESS SYNDROMEß
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
SE9802794D0 (sv) New compounds
DE60307237D1 (de) Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheiten
ATE353667T1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
ATE345788T1 (de) Verwendung von mek hemmern zur behandlung von virusvermitteltem hämorragischem schock oder fieber
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
DE50013934D1 (de) Verwendung von r-arylpropionsäuren zur herstellung von arzneimitteln, zur behandlung von erkrankungen bei mensch und tier, welche durch die hemmung der aktivierung von nf-kappa b therapeutisch beeinflusst werden können
ATE320255T1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
IS7200A (is) Notkun á írbesartan til framleiðslu á lækningalyfjum sem notuð eru til að koma í veg fyrir eða meðhöndla lungnaháþrýsting
ATE333869T1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
DE60232733D1 (de) Alternativ gesplicter zirkulierender gewebefaktor
WO2004012660A3 (en) Mk2 interacting proteins
ATE423129T1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
ATE178486T1 (de) Verwendung von kardiotonischen mitteln und inhibitoren der stickstoffoxidsynthese zur linderung von pathologisch verringertem blutdruck

Legal Events

Date Code Title Description
8363 Opposition against the patent